Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Employees - 6,
CEO - Dr. Andrew Regan,
Sector - Healthcare,
Country - US,
Market Cap - 4.58M
Altman ZScore(max is 10): 1.44, Piotroski Score(max is 10): 6, Working Capital: $544293000, Total Assets: $3206020000, Retained Earnings: $1225949000, EBIT: 39456000, Total Liabilities: $1983513000, Revenue: $2133939000
- Current Price $5.75 - Analyst Target Price $-| Ticker | CDT |
| Index | RUT |
| Curent Price | 5.75 |
| Change | 0.88% |
| Market Cap | 4.58M |
| Average Volume | 204.06K |
| Income | -19.40M |
| Sales | 0.00M |
| Book Value/Share | 4.24 |
| Cash/Share | 2.67 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 6 |
| Moving Avg 20days | -18.33% |
| Moving Avg 50days | -44.15% |
| Moving Avg 200days | -94.55% |
| Shares Outstanding | 0.63M |
| Earnings Date | - |
| Inst. Ownership | 4.30% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 1.36 |
| Price/Cash | 2.15 |
| Price/FCF | - |
| Quick Ratio | 1.31 |
| Current Ratio | 1.31 |
| Debt/Equity | 1.07 |
| Return on Assets | -316.98% |
| Return on Equity | -89.65% |
| Return on Investment | -701.48% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 31.51 |
| BETA(β) | 2.12 |
| From 52week Low | 11.05% |
| From 52week High | -99.88% |
| EPS | -266.45 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -263.11% |
| Sales Y/Y | - |
| EPS Q/Q | 72.62% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 1.21 |
| Perf Week | -3.35% |
| Perf Month | -30.07% |
| Perf Quarter | -67.51% |
| Perf Year | -99.87% |
| Perf YTD | -94.41% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer